Edition:
United States

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

108.40EUR
4:18am EST
Change (% chg)

€-0.25 (-0.23%)
Prev Close
€108.65
Open
€108.40
Day's High
€108.60
Day's Low
€107.85
Volume
336,904
Avg. Vol
1,847,547
52-wk High
€123.90
52-wk Low
€86.03

Select another date:

Sun, Nov 19 2017

BRIEF-Peptidream announces discovery collaboration agreement with Bayer

* Peptidream announces discovery collaboration agreement with bayer

BRIEF-PeptiDream announces discovery collaboration agreement with Bayer AG

* Says it announced today that it has entered into a multi-target discovery collaboration with Germany-based Bayer AG

Bayer hires new blood to stem 'Amazon effect' in consumer health

FRANKFURT German drugmaker Bayer has hired the head of Nestle's baby food business to help it reverse a drop in revenue from consumer health brands, which often fail to appeal to buyers on Amazon and other online platforms.

UPDATE 2-Bayer hires new blood to stem 'Amazon effect' in consumer health

* Amazon also expected to muscle in on prescription drugs (Adds details of online mail order in OTC, prescription drugs)

Bayer taps Nestle nutrition head to lead consumer care unit

FRANKFURT, Nov 15 Bayer has hired the head of Nestle's baby food business to run its embattled consumer health division, replacing Erica Mann in March next year.

Loxo signs lucrative cancer drug deal with Bayer, but shares fall

Loxo Oncology on Tuesday signed a collaboration agreement for its promising cancer drugs with Germany's Bayer AG that could be worth up to $1.55 billion to the tiny U.S. company, but its shares fell 11 percent as the deal appeared to end near-term likelihood of a takeover.

UPDATE 4-Loxo signs lucrative cancer drug deal with Bayer, but shares fall

Nov 14 Loxo Oncology on Tuesday signed a collaboration agreement for its promising cancer drugs with Germany's Bayer AG that could be worth up to $1.55 billion to the tiny U.S. company, but its shares fell 11 percent as the deal appeared to end near-term likelihood of a takeover.

UPDATE 2-Loxo, Bayer to co-develop cancer drugs in up to $1.55 bln deal

Nov 14 Loxo Oncology will collaborate with Germany's Bayer to develop and commercialize two of its cancer therapies, the companies said, in a deal that could bring the U.S. drug developer up to $1.55 billion over the next few years.

BRIEF-Bayer may terminate Loxo agreement if Larotrectinib is unapproved

* Agreement with Bayer includes standstill provision preventing Bayer from acquiring 5 percent or more of co's voting securities​

BRIEF-Bayer, Loxo Oncology form partnership to develop, commercialise cancer drugs​

* Says it and loxo oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer​

Select another date: